Bruker Overview
- Year Founded
-
1960
- Status
-
Public
- Employees
-
11,085
- Stock Symbol
-
BRKR
- Investments
-
113
- Share Price
-
$56.47
- (As of Friday Closing)
Bruker General Information
Description
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Contact Information
Website
www.bruker.comCorporate Office
- 40 Manning Road
- Billerica, MA 01821
- United States
Corporate Office
- 40 Manning Road
- Billerica, MA 01821
- United States
Bruker Stock Performance
As of 20-Nov-2026, Bruker’s stock price is $56.47. Its current market cap is $8.62B with 153M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $56.47 | $62.10 | $32.37 - $68.98 | $8.62B | 153M | 2.33M | -$1.10 |
Bruker Financials Summary
As of 30-Sep-2026, Bruker has a trailing 12-month revenue of $3.51B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 11,521,966 | 8,933,847 | 11,192,489 | 11,061,856 |
| Revenue | 3,513,100 | 3,436,500 | 3,366,400 | 2,964,500 |
| EBITDA | 185,700 | 287,800 | 429,300 | 668,000 |
| Net Income | (123,400) | (8,600) | 113,100 | 427,200 |
| Total Assets | 5,828,300 | 6,241,400 | 5,806,700 | 4,249,900 |
| Total Debt | 1,713,400 | 2,042,900 | 2,245,300 | 1,379,600 |
Bruker Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bruker Comparisons
Industry
Financing
Details
Bruker Competitors (14)
One of Bruker’s 14 competitors is Revvity, a Corporation company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Revvity | Corporation | Waltham, MA | ||||
| Sartorius | Corporation | Goettingen, Germany | ||||
| Sagence Technologies | Corporation | Calgary, Canada | ||||
| GE HealthCare Technologies | Corporation | Chicago, IL | ||||
| BioMérieux | Formerly PE-Backed | Marcy-l'Etoile, France |
Bruker Patents
Bruker Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| DE-202025105706-U1 | Microfluidic system for microfluidic flow cells | Active | 23-Sep-2025 | ||
| DE-102025135265-B3 | Device and method for providing laser radiation in the form of a series of successive pulses | Active | 03-Sep-2025 | ||
| EP-4838373-A1 | Method of storing and querying measurement data | Pending | 09-May-2025 | ||
| WO-2026234231-A1 | Method of storing and querying measurement data | Pending | 09-May-2025 | ||
| WO-2026233508-A1 | Method for determining a minimum inhibitory concentration, and analysis method | Pending | 07-May-2025 |
Bruker Signals
Bruker Investments & Acquisitions (113)
Bruker’s most recent deal was a Later Stage VC with Atinary. The deal was made on 14-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Atinary | 14-Aug-2026 | Later Stage VC | Business/Productivity Software | ||
| MIMETAS | 10-Aug-2026 | Later Stage VC | Discovery Tools (Healthcare) | ||
| Noscendo GmbH (DISQVER Clinical Metagenomics Platform) | 15-Jul-2026 | Corporate Asset Purchase | Biotechnology | ||
| Tofwerk | 06-Jan-2026 | Merger/Acquisition | Electronic Equipment and Instruments | ||
| Molzym | 19-Nov-2025 | Merger/Acquisition | Diagnostic Equipment |
Bruker ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
23.31 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Bruker Exits (8)
Bruker’s most recent exit was on 12-Feb-2025 from Terrain Bio. The exit was categorized as with 9 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Terrain Bio | 12-Feb-2025 | Completed |
|
||
| Tome Biosciences | 12-Dec-2023 | Completed |
|
||
| Haystack Oncology | 16-Nov-2022 | Completed |
|
||
| Ionpath | 24-Sep-2020 | Completed |
|
||
| Bruker (ICP-MS Business) | 19-May-2010 | Merger/Acquisition | Completed |
Bruker Affiliates
Subsidiaries (31)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Acuity Spatial Genomics | Santa Barbara, CA | 2021 | |
| MIRO Analytical | Wallisellen, Switzerland | 2016 | |
| Canopy Biosciences | Saint Louis, MO | 2016 | |
| Zontal | Billerica, MA | 2016 | |
| Molecubes | Gent, Belgium | 2014 |
Bruker FAQs
-
When was Bruker founded?
Bruker was founded in 1960.
-
Where is Bruker headquartered?
Bruker is headquartered in Billerica, MA.
-
What is the size of Bruker?
Bruker has 11,085 total employees.
-
What industry is Bruker in?
Bruker’s primary industry is Diagnostic Equipment.
-
Is Bruker a private or public company?
Bruker is a Public company.
-
What is Bruker’s stock symbol?
The ticker symbol for Bruker is BRKR.
-
What is the current stock price of Bruker?
As of 20-Nov-2026 the stock price of Bruker is $56.47.
-
What is the current market cap of Bruker?
The current market capitalization of Bruker is $8.62B.
-
What is Bruker’s current revenue?
The trailing twelve month revenue for Bruker is $3.51B.
-
Who are Bruker’s competitors?
Revvity, Sartorius, Sagence Technologies, GE HealthCare Technologies, and BioMérieux are some of the 14 competitors of Bruker.
-
What is Bruker’s annual earnings per share (EPS)?
Bruker’s EPS for 12 months was -$1.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process